A New Comprehensive Approach to Assess the Probability of Success of Development Programs Before Pivotal Trials

Area of Science:

• Pharmaceutical Development
• Biostatistics
• Decision Analysis

Background:

• Transitioning clinical development programs to pivotal trials involves significant uncertainty and necessitates robust decision-making tools.
• Current reliance on industry benchmarks for probability of success (PoS) is often inaccurate, misaligned with commercial goals, and leads to inflated financial projections.
• Existing methods lack transparency and systematic evaluation of risks influencing program outcomes.

Purpose of the Study:

• To develop and present a novel framework for assessing the probability of success (PoS) of pharmaceutical programs prior to pivotal trials.
• To establish a comprehensive definition of success that includes pivotal trial outcomes, regulatory approval, and market access requirements.
• To enhance decision-making processes for drug development portfolio prioritization.

Main Methods:

• Development of a four-step framework for PoS assessment.
• Utilizes an innovative Bayesian approach to synthesize diverse evidence.
• Integrates pivotal trial success, regulatory approval, and market access criteria into the PoS calculation.

Main Results:

• The proposed framework provides a systematic and transparent method for evaluating program PoS.
• Demonstrates a more accurate and reliable estimation of PoS compared to traditional benchmarks.
• Facilitates informed prioritization of drug development projects.

Conclusions:

• The new PoS framework offers a significant improvement for decision-making in pharmaceutical development.
• Its systematic and transparent nature aids organizations in navigating the uncertainties of late-stage clinical trials.
• Adoption of this framework can lead to more realistic financial forecasting and optimized resource allocation.